Mary Beth Ritchey, MSPH, PhD, FISPE, has dedicated her career to better understanding the safety and effectiveness of medical products. With experience spanning industry, academia, and government, including a tenure as Chief Epidemiologist at the US FDA/CDRH, she offers a unique fluency across sectoral priorities. As Principal and Owner of Med Tech Epi, LLC, Dr. Ritchey provides scientific and technical leadership in real-world evidence strategy, medical product surveillance, and evidence generation that informs regulatory, payer, clinical, and patient decision-making. Her expertise encompasses multi-stakeholder international clinical research, strategic planning and coordination of scientific programming, and the development of rigorous methodological frameworks for observational medical product research.
Dr. Ritchey is an Associate Research Professor in the Center for Pharmacoepidemiology and Treatment Sciences at Rutgers University and is the Immediate Past President of the International Society for Pharmacoepidemiology (ISPE). She holds bachelor’s degrees in chemistry (Duke University) and nursing (University of North Carolina, Chapel Hill), and Master’s and Doctoral degrees in epidemiology from the UNC Gillings School of Global Public Health.
Conflict of Interest Disclosures: Associate Research Professor at Rutgers University working on NIH-funded grants and hold ownership interests in Med Tech Epi, LLC and CERobs Consulting, LLC, both of which provide consulting services to pharmaceutical and medical device companies.